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ABSTRACT 
BACKGROUND AND OBJECTIVE: Stroke is the second most common cause of death and a major cause of 
disability in individuals aged over 65 years, worldwide. Considering the complex pathological process of ischemia, 
use of one single agent does not seem ideal for treatment. Therefore, studies in search of effective compounds and 
methods are under way. In recent years, increased attention has been paid to medicinal plants as potential sources 
for the treatment of ischemia and reperfusion. This study aimed to introduce the pathogenesis of cerebral ischemia 
and review the effects of medicinal plants and their mechanisms of action in cerebral ischemia. 
METHODS: In this study, articles indexed in scientific databases including ISI, SID, PubMed, PubMed Central, 
Scopus, and Web of Science were evaluated, using the following keywords in Farsi and English: "Ischemia and 
reperfusion", "medicinal herbs", and "antioxidant properties". 
FINDINGS: The review of conducted studies showed that medicinal plants and their compounds are capable of 
reducing infarct volume, cerebral edema, neuronal damages, sensory problems, and motor disorders through 
reducing oxidative and nitrative stress. Moreover, these plants are able to decrease the expression of inflammatory 
mediators, inhibit DNA fragmentation and oxidative DNA damage, reduce microglial and astrocyte activities, 
increase the expression of mitochondrial genes, inhibit apoptotic protein expression, reduce eicosanoids, and boost 
anti-apoptotic protein expression. 
CONCLUSION: Medicinal herbs and their compounds are able to diminish the damages caused by cerebral 
ischemia through several pathways; therefore, they can be used as new sources against cerebral ischemia.  
KEY WORDS: Antioxidant Properties, Ischemia, Medicinal Herbs, Reperfusion. 
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Introduction 
Stroke is a major cause of disability and the third 
leading cause of mortality. In recent decades, the 
incidence of stroke has significantly increased, 
particularly in developing countries (1). 
Approximately 20% of these patients die within the 
first month after stroke and those who survive for more 
than six months are highly dependent on others. These 
patients suffer from complications such as partial body 
paralysis, memory disorders, and cognitive/lingual 
impairments (2).  
Factors increasing the risk of stroke include high 
blood pressure, diabetes mellitus, smoking, alcohol 
abuse, dyslipidemia, and hypercholesterolaemia (3). 
Overall, 15% of strokes are caused by hemorrhage, 
while 85% of these cases occur due to ischemia (2). 
Cerebral ischemia leads to neurological disorders (e.g., 
motor, sensory, and visual disorders), speech disorders, 
and neuropsychiatric defects such as reduced cognitive 
function, apraxia, cognitive impairment, anterograde 
amnesia, and impaired spatial learning and memory 
(4). 
The brain requires 25% of cardiac output for its 
metabolic requirements. Therefore, any decline in 
cerebral blood flow may lead to ischemia and 
neurodegenerative disorders (5). Ischemia is caused by 
factors such as thrombosis, embolism, and reduced 
systemic hypoperfusion (2).  
During ischemia, temporary or permanent decline 
in blood flow to the brain leads to the limited transfer 
or loss of glucose and oxygen, required for cellular 
homeostasis. At this stage, events such as stimulus-
induced cytotoxicity, acidosis, ion imbalance, 
oxidative stress, lipid peroxidation, inflammation, and 
apoptosis lead to cell death. In the next stage, 
reperfusion causes mitochondrial dysfunction, release 
of glutamates and inflammatory mediators, production 
of reactive oxygen species (ROS), and lipid 
peroxidation (1). Due to the complex pathological 
process of ischemia, use of one single agent does not 
seem ideal for treatment (1). To date, except for 
recombinant tissue plasminogen activator (R-TPA), no 
effective treatment has been proposed for ischemia to 
alleviate the symptoms within less than three hours 
following their onset (2). Given the fact that apoptotic 
death occurs in the late phase of ischemia at low rates, 
use of apoptosis inhibitors is the next phase of 
treatment (6). In recent years, use of medicinal herbs 
and their active constituents has been emphasized as a 
potential source for the treatment of ischemia-
reperfusion (7). Significant attention has been paid to 
these herbs due to their recognition as safe substances, 
cost-effectiveness, availability, long-term use, 
consumers' preference, and limited side-effects (8).  
So far, several studies have been conducted on the 
neuroprotective effects of medicinal plants. Also, a 
number of studies have investigated the effects of 
medicinal herbs and their effective compounds on 
cerebral ischemia and have identified their 
mechanisms of action. In the present study, in addition 
to introducing cerebral ischemia and its pathogenesis, 
we aimed to review the literature on the protective 
effects of medicinal herbs on cerebral ischemia and 
their mechanisms of action.  
Pathogenesis of cerebral ischemia and reperfusion: 
During a stroke, two cellular responses occur in brain 
tissues: 
1- Severe response to ischemia, reduced energy, and 
production of free radicals: During ischemia, due to 
decreased oxygen concentration, the brain starts to 
consume anaerobic glycolysis, although this process is 
inefficient in terms of energy supply (9). During 
anaerobic glycolysis, pyruvate converts into lactate by 
lactate dehydrogenase, and thus lactate concentration 
in ischemic tissues increases, leading to intracellular 
acidosis (10). Free radicals, which are produced by the 
breakdown of adenosine triphosphate (ATP) 
metabolites via xanthine oxidase, along with 
prostaglandins, attack unsaturated fatty acids (via 
plasma membrane polyunsaturated fatty acids), 
causing damage and increased permeability. 
Mitochondrial respiratory chain is the main source 
for ROS production. Necrotic cell death occurs, 
following mitochondrial dysfunction. Endothelial cell 
death destroys the blood-brain barrier and results in 
brain edema (11). Damage to energy-dependent ion 
pumps leads to cellular depolarization and release of 
glutamates into the extracellular space. Afterwards, N-
methyl-D-aspartate receptors (NMDAs) are activated, 
resulting in the increased level of intracellular calcium, 
which is responsible for the production of ROS and 
nitric oxide. A nitrite proxy is produced by the 
combination of nitric oxide and superoxide, leading to 
lipid peroxidation (12).  
2-Delayed response to ischemia, inflammation: The 
second wave of cell death in response to ischemia is 
caused by inflammatory neuronal mediators. During 
ischemia, the activated microglia can produce 
inflammatory cytokines such as tumor necrosis factor-
α, interleukin-1 beta, and other cytotoxic molecules 
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such as nitric oxide and ROS (13). Similar to 
microglia, astrocytes are able to produce inflammatory 
factors such as cytokines, chemokines, and nitric 
oxide. Cytokines increase the expression of cell 
adhesion molecules. Through this process, leukocytes 
adhere to arterial walls, migrate to brain tissues, start 
to secrete inflammatory mediators, and cause 
secondary brain injury within four to six hours 
following the onset of ischemia (14). 
Inflammatory changes of neurons eventually 
destroys the blood-brain barrier, causes cerebral 
edema, and induces cell death (2). Several 
biochemical, molecular, and electrophysiological 
cascades are responsible for cell death after ischemia. 
In the early stage of ischemia, apoptosis is the major 
form of cell death, i.e., a simple and rapid death, 
followed by the release of inflammatory cellular 
contents. This type of cell death mainly occurs in the 
absence of energy (e.g., the early stage of ischemia); in 
fact, necrotic death requires less energy and facilitates 
ischemia (6).  
Apoptosis is identified with processes such as the 
swelling of cytoplasmic organelles and nucleus, 
mitochondrial destruction, and disintegration of plasma 
membranes (15). In the late phase of ischemia, 
apoptotic cell death is characterized with the 
contraction of nuclear chromatin, DNA fragmentation, 
shrinkage of cytoplasm, and bubble-shape of the 
membrane (16). Apoptotic death prevents the release 
of organelle contents (e.g., lysosomes) into the 
extracellular matrix, resulting in secondary damage to 
the tissues through inflammation. Apoptotic death 
normally occurs when there is sufficient energy 
supply, e.g., during reperfusion (6). 
Oxidative stress, as a major cause of neuronal 
injury during cerebral ischemia, arises when the 
physiological balance between oxidants and 
antioxidants is disturbed in favor of the former, 
causing serious injuries to the tissues. Oxidative stress 
leads to the formation of ROS and reactive nitrogen 
species and causes multiple adverse outcomes 
including mitochondrial dysfunction, increased 
calcium level, reperfusion injury, and inflammation 
(17). Due to the significant presence of oxygen, ROS 
production is more probable in aerobic tissues such as 
brain tissues. Brain cells are responsible for almost 
20% of the total oxygen consumption, despite the fact 
that the brain only accounts for 2% of body weight 
(18). Increased ROS production causes oxidative 
damage to cellular components, changes nucleic acid 
bases, induces single- and double-strand breaks in 
DNA structure, and destroys the glycosylated bonds 
between the ribose and bases (19). The brain is 
protected against these free radicals by endogenous 
free radicals (e.g., ascorbate and alpha-tocopherol) or 
endogenous antioxidant enzymes (e.g., superoxide 
dismutase, glutathione peroxidase, and catalase).  
Nuclear factor-erythroid 2-related factor-2 
(Nrf2)/antioxidant responsive element (ARE) pathway 
is one of the main pathways against oxidative stress, 
which regulates the cellular redox status. Under normal 
homeostatic conditions, Nrf2 is inhibited by Keap1. 
However, in the presence of ROS, Nrf2 is abandoned 
by Keap1 and is transferred into the nucleus, where it 
connects to ARE in the promoter region of genes, 
encoding antioxidant enzymes, and induces the 
production of antioxidant enzymes (20). 
Researchers have shown that Nrf2 expression and 
production of antioxidant enzymes increase during 
cerebral ischemia; however, due to their limited 
capacity, the concentration of free radicals starts to rise 
(17). According to previous research, numerous 
compounds (such as polyphenols) with antioxidant 
properties, which are found in some food sources, are 
able to increase the expression of transcription factor 
Nrf2, followed by the increased production of 
antioxidant enzymes in brain cells (17, 21).   
High concentrations of iron (which catalyzes the 
production of free radicals) and unsaturated fatty acids 
in the brain are among other factors, which increase 
brain sensitivity to oxidative stress (18). It has been 
reported that during ischemia, the concentration of free 
fatty acids, particularly arachidonic acids, significantly 
increases (13).  
In fact, the increase in intracellular calcium during 
ischemia activates phospholipase C and A, resulting in 
the hydrolysis of phospholipids and release of fatty 
acids. Re-synthesis of phospholipids requires the 
presence of ATP. As a result, following the increase in 
intracellular calcium concentration and decreased ATP 
level in ischemia, free fatty acids are released and the 
membrane is damaged (22). Release of free fatty acids 
is followed by various adverse effects such as the 
inhibition of oxidative phosphorylation, conversion of 
arachidonic acids to eicosanoids (e.g., thromboxane 
and prostaglandin) by cyclooxygenase (COX), lipid 
peroxidation by free radicals, mediated chain reactions 
by lipid peroxidation, and cytotoxicity induced by lipid 
peroxide products (e.g., hydroxynonenal), which might 
be followed by apoptosis (17).  
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As recently demonstrated, impaired mitochondrial 
gene expression during cerebral ischemia damages 
neurons in the CA1 region of the brain (23). Induction 
of global cerebral ischemia in rats reduces the 
expression of cytochrome oxidase, encoded by 
mitochondrial DNA; this process disturbs the energy 
metabolism and causes oxidative phosphorylation (24). 
It has been reported that Ginkgo biloba and its active 
compound, i.e., bilobalide, are able to regulate COX 
expression and reduce ischemia-induced neuronal 
damages (24). 
In addition to intracellular pathological events, 
disruption in signaling pathways in the cellular space, 
involved in cell-to-cell or cell-to-matrix interactions, 
contributes to neuronal damages during ischemia. It 
has been indicated that the induction of ischemia-
reperfusion in rats increases the expression of matrix 
metalloproteinase-2 and metalloproteinase-9. 
Therefore, the activated enzymes facilitate the 
destruction of components in the basement membrane 
matrix and disintegrate brain capillaries. Consequently, 
genetic and pharmacological inhibition of these 
enzymes has been considered in the treatment and 
prevention of cerebral ischemia (25). Considering the 
abovementioned points, new strategies for the 
treatment of ischemia and stroke include the 
identification of ROS-neutralizing compounds, 
chelating metal ions, non-steroidal, anti-inflammatory 
drugs, anti-apoptotic agents, and bioenergetic 
medicines (used either solely or in combination) (8).  
The scavenging effects of free radicals, chelating 
effect of metal ions, and anti-inflammatory properties 
of medicinal plants have been revealed in animal and 
human models. Therefore, recent research has focused 
on the use of medicinal plants and their active 
compounds in the treatment of nervous system 
disorders and possibly ischemia (26).  
The studied medicinal plants for the treatment of 
ischemia-reperfusion: In this section, we present a 
summary of studies on the protective effects of 
medicinal plants and their active compounds. The 
scientific name, local name, the used parts, studied 
concentrations, and the mechanisms of influence in 
these plants are also discussed (table 1). 
 
Table 1. The studied medicinal plants for the treatment of cerebral ischemia-reperfusion 
Local name 
 (scientific name) 
Family The used parts Concentration Effects (reference) 
Olive 
 (Olea europaea) 
Oleaceae 
Olive leaf extract 
Oral treatment with 50, 75, and 
100 mg/kg of the extract in male 
Wistar rats with cerebral 
ischemia 
Reduced LDL/HDL ratio, reduced infarct volume, cerebral edema, blood-
brain barrier permeability, and neurological defects (27) 
The ethanolic extract of 
olive leaf 
Oral pretreatment with 100 
mg/kg of the extract in male 
Wistar rats 
Reduced production of nitric oxide and superoxide, reduction of lipid 
peroxide, increased antioxidant enzymes, and reduced neuronal damages in 
the CA1 region of the hypothalamus (28) 
Oil 
Oral pretreatment with a dose of 
1 ml/kg  in male Wistar rats 
Reduced infarct volume, decreased neuromotor disorders, and reduced 
number of damaged eosinophilic neurons in ischemic areas (7) 
Oil 
Oral pretreatment with 0.25, 0.5, 
and 0.75 ml/kg doses in male 
Wistar rats 
Reduction in infarct volume, cerebral edema, blood-brain barrier 
permeability, and neurological defects (29) 
Extract 
Oral treatment with 50, 75, and 
100 mg/kg concentrations in male 
Wistar rats 
Increased levels of cholesterol, cholesterol ester, and triglyceride in the brain 
(30) 
Pomegranate 
 (Punica granatum L.( 
Punicaceae Pomegranate extract 
Oral treatment with the extract at 
250 and 500 mg/kg in male 
Wistar rats with cerebral 
ischemia 
Decline in lipid peroxides (e.g., malondialdehyde and nitric acid), increased 
level of antioxidant enzymes (e.g., superoxide dismutase, glutathione 
peroxidase, and glutathione reductase) in the brain, reduced brain 
inflammatory factors (NF-κB p65, and TNF-α), and increased production of 
IL-10 and ATP (5) 
Cherokee Rose 
 (Rosa laevigata) 
Rosaceae Flavonoid-rich extracts 
Oral treatment with 50, 100, and 
200 mg/kg of the extracts in male 
Sprague-Dawley rats with 
cerebral ischemia 
Increased survival of rats, reduced DNA fragmentation, decreased 
expression of apoptotic molecules, increased expression of anti-apoptotic 
proteins, and decreased expression of inflammatory mediators (e.g., iNOS, 
MMP-9, COX-2, TNF-α, IL-1ß, and IL-4) (1) 
Garlic  
(Allium sativum L.) 
Alliaceae 
Hydroethanolic extract 
of garlic peel and seeds 
Oral treatment at a concentration 
of 360 mg/kg in male Wistar rats 
with cerebral ischemia 
Decreased expression of NMDA subunits such as NR1 and NR2B, increased 
ATP production in the brain, and inhibition of the decline in neuronal 
nuclear antigens (31) 
Absinthium 
 (Artemisia absinthium) 
Asteraceae 
Methanolic extract of 
aerial parts 
Oral doses (100 and 200 mg/kg) 
in male Swiss albino rats with 
focal cerebral ischemia 
Reduced infarct volume, improved short-term memory and balance, reduced 
lipid peroxidation, and increased level of endogenous antioxidants (32) 
Basil (Ocimum basilicum) Lamiaceae 
Ethyl acetate leaf 
extracts 
Oral treatment with 100 and 200 
mg/kg of the extracts in male 
Swiss albino rats with cerebral 
ischemia 
Reduced infarct volume, reduced lipid peroxidation, increased glutathione in 
the brain, and increased short-term memory and balance (3) 
Ginkgo 
 (Ginkgo biloba) 
Ginkgoaceae 
Extract and bilobalide 
Oral treatment with 25, 50, and 
100 mg/kg of the extracts and 
isolated terpene at 3 and 6 mg/kg  
in male rats with cerebral 
ischemia 
Reduced death of neurons and increased expression of mitochondrial genes 
such as COX II (24) 
Extract 
Intraperitoneal injection of 100 
mg/ml of the extract in male rats 
with focal cerebral ischemia 
Increased level of ascorbates and preservation of pyruvates (10) 
Extract, bilobalide, and 
ginkgolide 
Oral treatment with 100 mg/kg of 
the extract and 6 mg/kg of the 
isolated compounds in male rats 
with cerebral ischemia 
Increased expression of heme-oxygenase 1, erythroid-2 related nuclear factor 
2, and endothelial vascular growth factor and a decline in inflammatory 
mediators such as microglial cells and astrocytes (21) 
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Hawthorn 
(Crataegus oxyacantha) 
Rosaceae Alcoholic extract 
Oral treatment with 100 mg/kg of 
the extract in male Sprague-
Dawley rats with cerebral 
ischemia 
Improved learning and memory, decreased infarct volume, increased 
glutathione in the brain, and reduced lipid peroxides (8) 
Ginseng  
(Panax ginseng) 
Araliaceae Hot aqueous extract 
Oral treatment with 350 mg/kg of 
the hot aqueous extracts in male 
Swiss albino rats with cerebral 
ischemia 
Reduced lipid peroxidation and increased glutathione, glutathione reductase, 
reductase, glutathione s-transferase, glutathione peroxidase, and superoxide 
dismutase (33) 
Bitter melon  
(Momordica charantia) 
Cucurbitaceae 
Lyophilized juice 
powder 
Oral pretreatment with 200 and 
800 mg/kg of lyophilized powder 
in male Swiss albino rats with 
cerebral ischemia 
Reduced infarct volume, reduced oxidative stress, and improved balance and 
short-term memory (34) 
Bunya  
(Araucaria bidwillii) 
Araucariaceae 
Bioflavonoid-rich 
extracts 
Oral pretreatment with 100 and 
200 mg/kg of the extracts in male 
Wistar rats with cerebral 
ischemia 
Reduced lipid peroxidation, increased glutathione, catalase, and superoxide 
dismutase, improved balance, and decreased neuronal damages (35) 
Green tea  
(Camellia sinensis) 
Theaceae 
Ethanolic extract 
Oral pretreatment with 0.5% and 
2% doses of the extract in male 
rats with cerebral ischemia 
Reduced infarct volume, reduced lipid peroxide and hydrogen peroxide, 
decreased apoptosis and neuronal damages, improved balance, and reduced 
8-oxo-dG (an index of oxidative DNA damage) (36) 
Ethanolic extract 
Oral pretreatment with 0.5% of 
the extract in male rats with 
cerebral ischemia 
Reduced infarct volume, reduced level of eicosanoids (e.g., leukotriene C4, 
prostaglandin E2, and thromboxane A2), decline in hydroperoxide and lipid 
peroxide, and reduced 8-oxo-dG (an index of oxidative DNA damage) (37) 
Epigallocatechin 
gallate compound 
Oral pretreatment with 25 and 50 
mg/kg doses in Sprague-Dawley 
male rats with cerebral ischemia 
Reduced infarct volume, reduced score on neurological deficits, and reduced 
levels of malondialdehyde and oxidized glutathione (38) 
Epigallocatechin 
gallate compound 
Intraperitoneal injection at a 
concentration of 50 mg/kg in 
male C57BL/6 rats with cerebral 
ischemia 
Reduced infarct volume and metalloproteinase gene expression (25) 
Epigallocatechin 
gallate compound 
Treatment with 25, 50, and 100 
mg/kg of the extract in male rats 
with cerebral ischemia 
Reduced neuronal damages at concentrations > 10 mg/kg (39) 
Skullcap  
(Scutellaria baicalensis) 
Labiatae Isolated flavonoids 
Oral pretreatment with 30, 40, 
and 60 mg/kg doses in Kunming 
male rats with cerebral ischemia 
Increased post-ischemia survival, reduced lipid peroxidation, increased 
superoxide dismutase level, and inhibition of platelet aggregation (40) 
Chamomile 
 (Matricaria recutita) 
Asteraceae 
Methanolic extract of 
plant capitols 
Oral treatment with 100, 200, and 
300 mg/kg of the extracts in male 
Sprague-Dawley rats with 
cerebral ischemia 
Reduced lipid peroxidation and increased levels of glutathione, catalase, 
superoxide dismutase, and thiol (41) 
Palmarosa 
 (Cymbopogon martinii) 
Gramineae Leaf essence 
Oral pretreatment with 50 and 
100 mg/kg doses in male Wistar 
rats with cerebral ischemia 
Reduced infarct volume, decreased lipid peroxidation, and increased 
catalase, superoxide dismutase, and thiol (42) 
Lavender 
 (Lavandula angustifolia) 
Labiatae 
Essence 
Intraperitoneal injection of 100, 
200, and 400 mg/kg of the extract 
in male rats with focal cerebral 
ischemia 
Reduced infarct volume and cerebral edema, decreased lipid peroxidation, 
increased catalase, superoxide dismutase, and total antioxidant capacity, 
improved expression of vascular endothelial growth factor, and no inhibition 
of apoptotic protein expression (43) 
Essence of aerial parts 
Oral treatment with 50, 100, and 
200 mg/kg doses in male Wistar 
rats with cerebral ischemia 
Decline in neurological deficit scores, infarct volume, and oxidative stress 
(44) 
Vitex (Vitex agnus 
castus) 
Verbenaceae Extract 
Oral treatment with a 
concentration of 80 mg/kg in 
ovariectomized mice with stroke 
Reduced infarct volume, neurological disorders, and emotional-behavioral 
disorders (45) 
Saffron 
(Crocus sativus) 
Iridaceae Extract 
Oral treatment with 100 mg/kg of 
the extract in male Wistar rats 
with stroke 
Reduced infarct volume, decreased cerebral edema, decreased 
malondialdehyde level, and increased antioxidant enzymes (46) 
Nowruzak 
(Salvia leriifolia Benth) 
Lamiaceae 
Aqueous and alcoholic 
extracts of the roots 
Intraperitoneal injection at 100, 
200, and 400 mg/kg doses in 
male Wistar rats with stroke 
Decreased malondialdehydes in brain tissues (4) 
Pennyroyal  
(Mentha longifolia) 
Lamiaceae Stem and leaf extracts 
Intraperitoneal injection at 50, 
100, and 200 mg/kg 
concentrations in male Wistar 
rats with stroke 
Reduced infarct volume, increased antioxidant capacity in the penumbra 
region and center of the brain, and reduced level of malondialdehydes in the 
brain (47) 
Grapes 
 (Vitis vinifera) 
Vitaceae 
Polyphenols of grape 
extract 
Oral treatment with 30 mg/kg of 
the extract in male rats with 
stroke 
Reduced DNA fragmentation and oxidative DNA damage, reduced activity 
of microglia and astrocytes, and decrease in delayed neuronal death (use of 
the extract after 4 days of ischemia was more effective than its use before 
ischemia) (48) 
Onion (Allium cepa) 
onion (Allium cepa) 
Amaryllidaceae 
Methanolic extract of 
onion peel and its 
edible parts 
Oral treatment with 100 and 200 
mg/kg of the extract in male 
Swiss mice with stroke 
Reduced infarct volume, improved short-term memory and motor 
coordination, and a significant decline in mitochondrial thiobarbituric-acid-
reactive substances (26) 
Yarrow 
 (Achillea millefolium) 
Asteraceae Extract 
50 and 500 mg/ml doses for 
alleviating stroke outcomes in 
female rats after ovary removal 
Reduced infarct volume, decreased neurological damages, and diminished 
motor-sensory disorders (49) 
 
Discussion 
So far, various studies have revealed the 
positive effects of a large number of medicinal 
plants on the devastating outcomes of ischemia-
reperfusion. Based on multiple studies, the active 
constituents of medicinal plants are capable of 
reducing infarct volume, cerebral edema, neuronal 
damages, and sensory, motor, and neurological 
disorders induced by ischemia.The proposed 
mechanisms for the protective effects of medicinal 
plants are as follows: 1) reduced oxidative and 
nitrative stress; 2) reduced lipid peroxidation; 3)  
 
 
inhibition of DNA fragmentation and oxidative 
damage; 4) decreased activity of microglia and 
astrocytes; 5) inhibition of apoptotic protein 
expression; 6) increased expression of 
mitochondrial genes; 7) reduced levels of 
eicosanoids (including leukotrienes), 
prostaglandins, and thromboxane; 8) increased 
expression of anti-apoptotic proteins; and 9) 
reduced expression of inflammatory mediators. In 
the majority of conducted studies on the protective 
effects of medicinal plants and their compounds 
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against cerebral ischemia, the toxic effects of these 
plants have been disregarded and the line between 
their therapeutic effects and toxicity has not been 
established yet.  
In a study by Chandrashekhar and colleagues, 
basil extracts at 10-2000 mg/kg concentrations 
were fed to rats and the lethal dose 50 (LD50) was 
determined after 24 hours. Finally, 10%, 20%, and 
30% extracts were studied for LD50 in the ischemic 
model (50). Moreover, Buch et al. investigated the 
acute toxicity of palmarosa extracts (500 mg/kg) in 
rats. Eventually, 10% and 20% doses were studied 
against ischemia in rats (42).  
However, other indices such as body weight 
and pathological/histological changes of organs 
were not evaluated in these studies. Therefore, to 
ensure the safety of consumers, it is advisable to 
examine the toxic effects of medicinal plants in 
addition to their therapeutic effects and active 
ingredients (51). The review of previous research 
on the protective effects of medicinal plants against 
ischemia indicated that the majority of these studies 
have been conducted on animal models, while so 
far, no research has been conducted on the 
protective effects of medicinal plants on cerebral 
ischemia in humans. Since the biochemical 
compounds of plants are metabolized during 
enzymatic processes of the body and liver (causing 
changes in the structure and influence of these 
plants), it is recommended that in addition to pre-
clinical studies, clinical studies be conducted, as 
well. During ischemia and reperfusion, cellular and 
molecular processes damage neuronal and non-
neuronal cells, as well as brain capillaries. Some of 
these processes include stimulus-induced 
cytotoxicity, oxidative and nitrative stress, lipid 
peroxidation, ion imbalance, release of 
inflammatory mediators, and mitochondrial 
dysfunction. Considering the complex pathological 
events in the process of ischemia-reperfusion, use 
of one single agent for treatment does not seem 
ideal. The review of studies on the protective 
effects of medicinal plants and their compounds 
indicated that these plants could reduce the damage 
caused by ischemia through several different 
pathways. Therefore, development of protective 
factors from medicinal plants could be a promising 
strategy for the treatment of ischemic brain damage 
and the associated neurological disorders.  
It is suggested that future studies focus on the 
effects of medicinal herbs and their constituents in 
human models. In addition, the toxicity and leakage 
of these compounds through the blood-brain barrier 
should be determined. 
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